Notice of Clarification of Application Submission Information for NOT-DA-19-022 "Notice: NIDA Accepting Competitive Revision Applications to Establish an Addiction Medicine Practice Based Research Network to Address the National Opioid Crisis"

Notice Number: NOT-DA-19-025

Key Dates
Release Date: February 27, 2019

Related Announcements
NOT-DA-19-022

Issued by
National Institutes of Health (NIH)

Purpose

The purpose of this notice is to clarify that in an exception to standard practice, NIH will accept applications in response to NOT-DA-19-022 "Notice: NIDA Accepting Competitive Revision Applications to Establish an Addiction Medicine Practice Based Research Network to Address the National Opioid Crisis" with certain specific submission guidelines.

Currently reads:

For R01 competitive revision supplements submitted in response to this notice, please submit all applications by March 11, 2019, not the standard due date referenced in the FOA.

Modified to read (new text is italicized):

In an exception to standard practice, NIDA will accept competitive revision applications submitted to PA-19-055, “Research Project Grant (Parent R01 Clinical Trial Required)” (https://grants.nih.gov/grants/guide/pa-files/pa-19-055.html) on March 11, 2019 for this competitive revision program only. No late competitive revision applications will be accepted.

Receipt dates indicated in the FOA do not apply to applications responding to this request for competitive revisions. For funding consideration, applicants must include "NOT-DA-19-022" (without quotation marks) in the Agency Routing Identifier field (Box 4B) of the SF424 R&R form. Applications without this identifier in Box 4B will not be considered for this special initiative. In addition, applicants should include a cover letter indicating that competitive revision applicants are responsive to the requirements of NOT-DA-19-022 receipt dates, and not the FOA application receipt dates.

All other aspects of the Notice remain unchanged.

Inquiries

Please direct all inquiries to:

Amy B. Goldstein, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-4124
Email:amy.goldstein@nih.gov